<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35543207</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1365-2060</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>54</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of medicine</Title>
          <ISOAbbreviation>Ann Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy.</ArticleTitle>
        <Pagination>
          <StartPage>1357</StartPage>
          <EndPage>1371</EndPage>
          <MedlinePgn>1357-1371</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/07853890.2022.2071977</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Vascular endothelial growth factor (VEGF) is a critical regulator of malignant pleural effusion (MPE) in non-small-cell lung cancer (NSCLC). Bevacizumab (BEV) and apatinib (APA) are novel VEGF blockers that inhibit lung cancer cell proliferation and the development of pleural effusion.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In this study, we established Lewis lung cancer (LLC) xenograft mouse models to compare the therapeutic effect of APA and BEV in combination with cisplatin (CDDP) against MPE. The anti-tumour and anti-angiogenic effects of this combination therapy were evaluated by <sup>18</sup>F-FDG PET/CT imaging, TUNEL assay and Immunohistochemistry.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The triple drug combination significantly prolonged the overall survival of the tumour-bearing mice by reducing MPE and glucose metabolism and was more effective in lowering VEGF/soluble VEGFR-2 levels in the serum and pleural exudates compared to either of the monotherapies. Furthermore, CDDP + APA + BEV promoted <i>in vivo</i> apoptosis and decreased microvessel density.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Mechanistically, LLC-induced MPE was inhibited by targeting the VEGF-MEK/ERK pathways. Further studies are needed to establish the synergistic therapeutic effect of these drugs in NSCLC patients with MPE.KEY MESSAGESCombined treatment of MPE with apatinib, bevacizumab and cisplatin can prolong the survival time of mice, reduce the content of MPE, decrease the SUV<sub>max</sub> of thoracic tumour tissue, down-regulate the content of VEGF and sVEGFR-2 in serum and pleural fluid, and promote the apoptosis of tumour cells. Angiogenesis and MPE formation can be inhibited by down-regulation of HIF-1α, VEGF, VEGFR-2, MEK1 and MMP-2 molecular signalling pathway proteins.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xiang</LastName>
            <ForeName>Zhangqiang</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Phase 1 Clinical Trial Center, Deyang People's Hospital, Deyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Xiangyu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Wenfeng</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Qian</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ni</LastName>
            <ForeName>Laichao</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dehghan Shasaltaneh</LastName>
            <ForeName>Marzieh</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Biology, Faculty of Science, University of Zanjan, Zanjan, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maghsoudloo</LastName>
            <ForeName>Mazaher</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Systems Biology and Bioinformatics, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Gang</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Anyue Hospital of Traditional Chinese Medicine, Second Ziyang Hospital of Traditional Chinese Medicine, Ziyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Jingbo</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China. The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Imani</LastName>
            <ForeName>Saber</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wen</LastName>
            <ForeName>Qinglian</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ann Med</MedlineTA>
        <NlmUniqueID>8906388</NlmUniqueID>
        <ISSNLinking>0785-3890</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
          <NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D040301">Vascular Endothelial Growth Factor Receptor-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="Y">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016066" MajorTopicYN="Y">Pleural Effusion, Malignant</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040301" MajorTopicYN="N">Vascular Endothelial Growth Factor Receptor-2</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Malignant pleural effusion</Keyword>
        <Keyword MajorTopicYN="N">apatinib</Keyword>
        <Keyword MajorTopicYN="N">bevacizumab</Keyword>
        <Keyword MajorTopicYN="N">cisplatin</Keyword>
        <Keyword MajorTopicYN="N">non-small-cell lung cancer</Keyword>
        <Keyword MajorTopicYN="N">vascular endothelial growth factor</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>5</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35543207</ArticleId>
        <ArticleId IdType="pmc">PMC9103356</ArticleId>
        <ArticleId IdType="doi">10.1080/07853890.2022.2071977</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Fitzmaurice C, Abate D, Abbasi N, et al. . 
Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and Disability-Adjusted Life-Years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1357–1768.</Citation>
        </Reference>
        <Reference>
          <Citation>Wong MCS, Lao XQ, Ho KF, et al. . 
Incidence and mortality of lung cancer: global trends and association with socioeconomic status. Sci Rep. 2017;7(1):14300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5662733</ArticleId>
            <ArticleId IdType="pubmed">29085026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferlay J, Soerjomataram I, Dikshit R, et al. . 
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25220842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartel DP.
MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3794896</ArticleId>
            <ArticleId IdType="pubmed">19167326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Froudarakis ME.
Pleural effusion in lung cancer: more questions than answers. Respiration. 2012;83(5):367–376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22584211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Economidou F, Margantopoulos G, Antoniou KM, et al. . 
The angiogenetic pathway in malignant pleural effusions: Pathogenetic and therapeutic implications. Exp Ther Med. 2010;1(1):3–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3490326</ArticleId>
            <ArticleId IdType="pubmed">23136584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zebrowski BK, Yano S, Liu W, et al. . 
Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res. 1999;5(11):3364–3368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10589746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M, Zeng Q, Li Y, et al. . 
Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model in vitro and in vivo. J Drug Target. 2020;28(9):961–969.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32374627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin W, Liu B, Yi M, et al. . 
Antifibrotic agent pirfenidone protects against development of Radiation-Induced pulmonary fibrosis in a murine model. Radiat Res. 2018;190(4):396–403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30016220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>E R, C A, J A, et al. . 
Angiogenic factors and angiogenesis inhibitors in exudative pleural effusions. Lung. 2005;183(3):185–195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16078040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>M B, A M, T P.. 
The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. Curr Oncol Rep. 2013;15(3):207–216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3674487</ArticleId>
            <ArticleId IdType="pubmed">23568600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roviello G, Ravelli A, Polom K, et al. . 
Apatinib: a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett. 2016;372(2):187–191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26797419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tao H, Meng Q, Li M, et al. . 
Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion. Thorac Cancer. 2018;9(2):298–304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5792722</ArticleId>
            <ArticleId IdType="pubmed">29297985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabang RL, Ganghiraj D, Fanucchi M, et al. . 
Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers. Expert Rev Respir Med. 2018;12(2):87–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29235400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott LJ.
Apatinib: a review in advanced gastric cancer and other advanced cancers. Drugs. 2018;78(7):747–758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29663291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>King M, Sensakovic WF, Maxim P, et al. . 
Line-Enhanced deformable registration of pulmonary computed tomography images before and after radiation therapy with Radiation-Induced fibrosis. Technol Cancer Res Treat. 2018;17:153303461774941. 1533034617749419.</Citation>
        </Reference>
        <Reference>
          <Citation>Li J, Qin S, Xu J, et al. . 
Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448–1454.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26884585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Qin S, Xu J, et al. . 
Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013;31(26):3219–3225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23918952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amaro A, Gangemi R, Piaggio F, et al. . 
The biology of uveal melanoma. Cancer Metastasis Rev. 2017;36(1):109–140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5385203</ArticleId>
            <ArticleId IdType="pubmed">28229253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li N, Wang Z, Yuan G, et al. . 
An oral small molecule VEGFR2 inhibitor, apatinib, in patients with recurrent or refractory cervical cancer: a real world study. J Oncol. 2020;2020:3852373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7327550</ArticleId>
            <ArticleId IdType="pubmed">32655637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao F, Zhang H, Yang X, et al. . 
Adverse events and management of apatinib in patients with advanced or metastatic cancers: a review. Neoplasma. 2020;67(4):715–723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32266817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao D, Hou H, Zhang X.. 
Progress in the treatment of solid tumors with apatinib: a systematic review. Onco Targets Ther. 2018;11:4137–4147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6056166</ArticleId>
            <ArticleId IdType="pubmed">30050305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fathi Maroufi N, Rashidi MR, Vahedian V, et al. . 
Therapeutic potentials of apatinib in cancer treatment: Possible mechanisms and clinical relevance. Life Sci. 2020;241:117106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31786193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian S, Quan H, Xie C, et al. . 
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102(7):1374–1380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21443688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura K, Taguchi E, Miura T, et al. . 
KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 2006;66(18):9134–9142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16982756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hicklin DJ, Ellis E.. 
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–1027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15585754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibuya M.
Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and Pro-Angiogenic therapies. Genes &amp; Cancer. 2011;2(12):1097–1105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3411125</ArticleId>
            <ArticleId IdType="pubmed">22866201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verheul HM, Hoekman K, Jornal AS, et al. . 
Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist. 2000;5(S1):45–50.</Citation>
        </Reference>
        <Reference>
          <Citation>Verheul HM, Hoekman K, Jorna AS, et al. . 
Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist. 2000;5(S1):45–50.</Citation>
        </Reference>
        <Reference>
          <Citation>Giantonio BJ, Catalano PJ, Meropol NJ, et al. . 
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern cooperative oncology group study E3200. J Clin Oncol. 2007;25(12):1539–1544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17442997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bagley SJ, Talento S, Mitra N, et al. . 
Comparative effectiveness of carboplatin/pemetrexed with versus without bevacizumab for advanced nonsquamous Non-Small cell lung cancer. J Natl Compr Canc Netw. 2019;17(5):469–477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6661525</ArticleId>
            <ArticleId IdType="pubmed">31085759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan M, Lin J, Liao G, et al. . 
Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: a Meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97(33):e11936.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6113026</ArticleId>
            <ArticleId IdType="pubmed">30113497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai ZG, Zhang ZT.. 
A systematic review and Meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer. OTT. 2018;11:7077–7087.</Citation>
        </Reference>
        <Reference>
          <Citation>Xu MD, Liu L, Wu MY, et al. . 
The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer. Oncogenesis. 2018;7(11):94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6255842</ArticleId>
            <ArticleId IdType="pubmed">30478299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>N D, X L, F L, et al. . 
Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion. Oncol Rep. 2013;29(6):2332–2340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23525453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J L, L P, G Z, et al. . 
Effective treatment for malignant pleural effusion and ascites with combined therapy of bevacizumab and cisplatin. Anticancer Res. 2016;36(3):1313–1318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26977031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acencio M, Puka J, Alvarenga VA, et al. . 
Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion. Oncotarget. 2017;8(62):105093–105102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5739623</ArticleId>
            <ArticleId IdType="pubmed">29285236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W, Xu J, Wang M, et al. . 
Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway. Int J Oncol. 2011;39(5):1213–1220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21785819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Socinski MA, Evans T, Gettinger S, et al. . 
Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e341S–e368S.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4694611</ArticleId>
            <ArticleId IdType="pubmed">23649446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alan S, Robert G, al P.. 
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17167137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu ZJ, Zhou YJ, Ding RL, et al. . 
In vitro and in vivo apatinib inhibits vasculogenic mimicry in melanoma MUM-2B cells. PLoS One. 2018;13(7):e0200845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6063421</ArticleId>
            <ArticleId IdType="pubmed">30052652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tissot C, Gay P, Brun C, et al. . 
Novel insights into the systemic treatment of lung cancer malignant pleural effusion. Clin Respir J. 2019;13(3):131–138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30737898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acencio MM, Puka J, Marchi E, et al. . 
A modified experimental model of malignant pleural disease induced by lung lewis carcinoma (LLC) cells. J Transl Med. 2015;13:302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4572443</ArticleId>
            <ArticleId IdType="pubmed">26373420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma X, Sun Y, Wang S, et al. . 
Establishment of a malignant pleural effusion mouse model with lewis lung carcinoma cell lines expressing enhanced green fluorescent protein. Transl Lung Cancer Res. 2012;1(3):170–178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4367562</ArticleId>
            <ArticleId IdType="pubmed">25806179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie SL, Yang MH, Chen K, et al. . 
Efficacy of arsenic trioxide in the treatment of malignant pleural effusion caused by pleural metastasis of lung cancer. Cell Biochem Biophys. 2015;71(3):1325–1333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25413961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nie K, Zhang Z, You Y, et al. . 
A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer. Thorac Cancer. 2020;11(1):8–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6938744</ArticleId>
            <ArticleId IdType="pubmed">31726490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee KH, Ko BH, Paik JY, et al. . 
Effects of anesthetic agents and fasting duration on 18F-FDG biodistribution and insulin levels in tumor-bearing mice. J Nucl Med. 2005;46(9):1531–1536.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16157537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie F, Ding RL, He WF, et al. . 
In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma. Drug Deliv. 2017;24(1):1410–1418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8241112</ArticleId>
            <ArticleId IdType="pubmed">28933203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weidner N, Semple JP, Welch WR, et al. . 
Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1–8.</Citation>
        </Reference>
        <Reference>
          <Citation>van der Leest C, Smit EF, Baas J, et al. . 
SUVmax during 18FDG-PET scanning in small cell lung cancer: similar information as in non-small cell lung cancer?
Lung Cancer. 2012;76(1):67–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21996089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braicu C, Buse M, Busuioc C, et al. . 
A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers. 2019;11(10):1618.[</Citation>
        </Reference>
        <Reference>
          <Citation>Yano S, Shinohara H, Herbst RS, et al. . 
Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol. 2000;157(6):1893–1903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1885766</ArticleId>
            <ArticleId IdType="pubmed">11106562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Musani AI.
Treatment options for malignant pleural effusion. Curr Opin Pulm Med. 2009;15(4):380–387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19436206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mallow C, Hayes M, Semaan R, et al. . 
Minimally invasive palliative interventions in advanced lung cancer. Expert Rev Respir Med. 2018;12(7):605–614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6309545</ArticleId>
            <ArticleId IdType="pubmed">29883216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grove CS, Lee YC.. 
Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med. 2002;8(4):294–301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12055392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fafliora E, Hatzoglou C, Gourgoulianis KI, et al. . 
Systematic review and Meta-analysis of vascular endothelial growth factor as a biomarker for malignant pleural effusions. Physiol Rep. 2016;4(24):e12978.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5210377</ArticleId>
            <ArticleId IdType="pubmed">28039396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simons M, Gordon E, Claesson-Welsh L.. 
Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016;17(10):611–625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27461391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. . 
Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor, the. Journal of Biological Chemistry. 1994;269(43):26988–26995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7929439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori R, Fujimoto D, Ito M, et al. . 
Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature. Oncotarget. 2017;8(29):48521–48524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5564666</ArticleId>
            <ArticleId IdType="pubmed">28591698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yano S, Herbst RS, Shinohara H, et al. . 
Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res. 2000;6(3):957–965.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10741721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan F, Samuel S, Gaur P, et al. . 
Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br J Cancer. 2011;104(8):1270–1277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3078594</ArticleId>
            <ArticleId IdType="pubmed">21407219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cabebe E, Wakelee H.. 
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol. 2007;8(1):15–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17634832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiu H, Li J, Liu Q, et al. . 
Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with paclitaxel. Cell Cycle. 2018;17(10):1235–1244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6110593</ArticleId>
            <ArticleId IdType="pubmed">29886786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoue S, Hartman A, Branch CD, et al. . 
Mda-7 in combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. Mol Ther. 2007;15(2):287–294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17235306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao X, Wang M-W, Luo J-M, et al. . 
Optimization of early response monitoring and prediction of cancer antiangiogenesis therapy via noninvasive PET molecular imaging strategies of multifactorial bioparameters. Theranostics. 2016;6(12):2084–2098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5039682</ArticleId>
            <ArticleId IdType="pubmed">27698942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goggi JL, Bejot R, Moonshi SS, et al. . 
Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors. J Nucl Med. 2013;54(9):1630–1636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23907757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>AD V. The lessons of GIST–PET and PET/CT: a new paradigm for imaging, The oncologist null(undefined) 2008. 8–13.</Citation>
        </Reference>
        <Reference>
          <Citation>Sun Y, Yu H, Ma J, et al. . 
The role of 18F-FDG PET/CT integrated imaging in distinguishing malignant from benign pleural effusion. PLoS One. 2016;11(8):e0161764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4999143</ArticleId>
            <ArticleId IdType="pubmed">27560933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakajima R, Abe K, Sakai S.. 
Diagnostic ability of FDG-PET/CT in the detection of malignant pleural effusion. Medicine (Baltimore. 2015;94(29):e1010. )</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4603013</ArticleId>
            <ArticleId IdType="pubmed">26200610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>C G, L.-F N, T M, et al. . 
Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth. Molecular Cancer Therapeutics. 2014;13(1):165–178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3893111</ArticleId>
            <ArticleId IdType="pubmed">24170768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collet G, Lamerant-Fayel N, Tertil M, et al. . 
Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth. Mol Cancer Ther. 2014;13(1):165–178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3893111</ArticleId>
            <ArticleId IdType="pubmed">24170768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu W, Puligandla M, Manola J, et al. . 
Angiogenic factor and cytokine analysis among patients treated with adjuvant VEGFR TKIs in resected renal cell carcinoma. Clin Cancer Res. 2019;25(20):6098–6106.</Citation>
        </Reference>
        <Reference>
          <Citation>Maxwell PH, Wiesener MS, Chang GW, et al. . 
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10353251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Henriet P, Emonard H.. 
Matrix metalloproteinase-2: Not (just) a "hero" of the past. Biochimie. 2019;166:223–232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31362036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rapisarda A, Melillo G.. 
Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res. 2012;114:237–267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22588059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carmeliet P.
VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69 Suppl 3:4–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16301830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koch S, Claesson-Welsh L.. 
Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb Perspect Med. 2012;2(7):a006502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3385940</ArticleId>
            <ArticleId IdType="pubmed">22762016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibuya M.
Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and Pro-Angiogenic therapies. Genes Cancer. 2011;2(12):1097–1105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3411125</ArticleId>
            <ArticleId IdType="pubmed">22866201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramjiawan RR, Griffioen AW, Duda DG.. 
Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy?
Angiogenesis. 2017;20(2):185–204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5439974</ArticleId>
            <ArticleId IdType="pubmed">28361267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Chen Y, Li F, et al. . 
Atezolizumab and bevacizumab attenuate cisplatin resistant ovarian cancer cells progression synergistically via suppressing Epithelial-Mesenchymal transition. Front Immunol. 2019;10:867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6498972</ArticleId>
            <ArticleId IdType="pubmed">31105696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao X, McDermott DF.. 
Combinations of bevacizumab with immune checkpoint inhibitors in renal cell carcinoma. Cancer J. 2018;24(4):171–179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30119080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schaaf MB, Garg AD, Agostinis P.. 
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis. 2018;9(2):115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5833710</ArticleId>
            <ArticleId IdType="pubmed">29371595</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
